Securing a positive return on biosimilar development depends
on multiple clinical and nonclinical factors. Critical to success is gaining
physician confidence in biosimilar products in order to drive adoption. We
conducted primary market research with 560 specialty physicians across the
United States and Europe to understand their perspectives on biosimilars and
their expectations for use. To fully identify nuances in physician attitude and
likelihood of adoption, we surveyed six different specialties and asked questions
about multiple drug classes used in specific indications. Through our market
research, we also uncover the trends in physician perceptions about biosimilars
over time and how physicians from different specialties and geographies vary
with respect to their opinions on automatic substitution, indication
extrapolation, drivers and constrainers of uptake, clinical concerns and
requirements, and competition from new innovative biologics.
This report is part of the Biosimilars Advisory Service. The
Biosimilars Advisory Service provides insight and analysis that is vital to
successful business planning in the rapidly evolving biosimilars space.
Quarterly webinars detailing major developments, analyst insight addressing key
market changes, therapeutic-area-specific primary research, and forecasting
modules are all included in a subscription to the Biosimilars Advisory Service.
Rely on us to keep you up-to-date on the biosimilars landscape and poised to
maximize opportunities for your business.
Questions Answered in This Report:
Understand surveyed physicians’ current level of familiarity with
What are the similarities and differences in physician opinions
with respect to physician specialty and region? How has familiarity with biosimilars evolved over time in Europe
and the United States? According to surveyed specialists, how similar are branded
reference biologics to their biosimilar counterparts?
Uncover physician perspectives on barriers and drivers to
biosimilar use and understand how barriers can be minimized and drivers can be
What are the most significant constraints to biosimilar use and
which are less important? Do they vary by country and over time?
What are considered to be the greatest challenges for biosimilar
manufacturers according to surveyed physicians? How do physician perceptions of drivers of biosimilar use differ
by region? How can biosimilar manufacturers maximize uptake by relying on the
strongest drivers? How will trust in biosimilar manufacturers influence biosimilar
uptake? Which companies are perceived to be the most trustworthy biosimilar
Understand physicians’ clinical trial data expectations for
What level of clinical trial data will convince different
specialists that biosimilars and branded biologics are comparable?
Understand how physicians’ attitudes translate to expected use
What are physicians’ opinions on indication extrapolation and
pharmacy-level substitution? How quickly do physicians expect to adopt biosimilars? How will price affect physicians’ uptake of biosimilars? To what extent will novel biologics be prescribed ahead of
biosimilars based on level of improvement and price?
United States and Europe.
Online quantitative survey of 560 specialty physicians in the United States and
To qualify for
participation, surveyed physicians had to meet the following criteria:
worked in clinical practice for a minimum of 3 years and a maximum of 30 years.
more than 75% of their professional time in clinical practice (with allowances
for academic physicians to have at least 51% of their professional time in
certain biologic drugs (depending on the specialty), including the following: TNF-alpha
antibodies in oncology, Erythropoiesis-stimulating
agents (ESAs), Granulocyte
colony-stimulating factors (G-CSFs), Pegylated
interferon-alphas, Somatropin, Insulins.
Biosimilars Advisory Service: Corporate Strategies
Biosimilars Advisory Service: Global Pipelines, Pathways, and Key Stakeholder
Biosimilars Advisory Service: US and EU Payer Perspectives
Biosimilars Advisory Service: Immunology & Infectious Disease
Biosimilars Advisory Service: Endocrinology and Nephrology
Biosimilars Advisory Service: Oncology